PM Tracker

More funds for the public health emergencies were chief among the "critical needs" the Office of Management and Budget highlighted for the government's coming fiscal quarter.

An investigational malaria vaccine booster from the University of Oxford maintained high efficacy levels a year after the initial shots—a feat in a disease area that scientists have long struggled to develop effective vaccines and therapies.

Another crop of health-focused additions to Apple’s eponymous wearable device are ready for harvest. The tech giant unveiled the new features during a keynote presentation Wednesday, with the rollout slated to begin later this month.

The FDA has approved Revance’s long-awaited Botox competitor, Daxxify. The cosmetic treatment temporarily removes moderate to severe glabbelar (frown) lines, and its effects have been shown to last for six months versus three for Botox.

VistaGen Therapeutics has been given the all-clear to continue a phase 3 trial of its social anxiety nose spray after the biotech paused enrollment following poor results from a similar late-stage study.

Morgan Health is making its latest strategic investment, this time with an eye on home health.

Using what was once a lesser-known regulatory option made world famous by the COVID-19 pandemic, the FDA has granted its first Emergency Use Authorization to a diagnostic test for monkeypox as cases continue to spread worldwide.

An appeals panel has ruled NICE may have erred in its recent rejection of Janssen’s Spravato for treatment-resistant depression in the U.K. Janssen in June contested the watchdog’s rebuff of its ketamine-derivative nasal spray, which earned a U.S. nod in conjunction with oral antidepressants back in 2019.

Mirati Therapeutics has taken the lid off updated data on KRAS inhibitor adagrasib in colorectal cancer. Having established itself as the front-runner in the space last year, the biotech has presented a new look at the data that largely reaffirm the earlier findings.

How can we predict the ability of a preclinical drug to inadvertently cause or intentionally inhibit cytokine secretion and T cell activation

Today’s healthcare systems are adapting to an ever changing landscape with declining margins, M&A pressures, and the need for staff flexibility due to shortages. Read our whitepaper and dive into the way healthcare providers can digitally transform day-to-day work by streamlining costs and increasing agility by removing manual paper burdens.

This paper explores how Medical Affairs is increasingly playing a key leadership role in evidence planning and generation (part 3 in a series).

Improve your congress competitive intelligence and cut down costs by 50%

Learn more about how the transition from early to late phase of a small molecule program plays a pivotal role in a program’s ultimate success.

Advanced research requires advanced tools. Our next-generation ELISA takes a fraction of the time to run eight analytes simultaneously while saving your sample volume. Simply load, scan, and insert your cartridge and come back to fully analyzed results in 75 minutes. Rethink your ELISA, with Ella.

Set a solid foundation for successful scale-up of buffer preparation.

Read through this library of resources to find out how you can strengthen innovation and efficiency, improve safety and quality, and prioritize resources to support your long-term goals.

What is the most suitable dosage form technology for the Oral Delivery of Lipid-Based Formulations?

Learn how formulation development for a PFS affects manufacturing to drive the industry toward optimizing delivery of injectable products and, ultimately, improving patient care.

What are key considerations for intranasal delivery in the treatment of acute and chronic conditions?

Learn more about how the versatility of Softgel Technology helped a customer with a volatile compound.

How can Lipid-Based Drug Delivery System help bring poorly soluble drugs to market?

Carla Vozone discusses the significant trends in the OINDP segment including large molecules and novel indications, changes within CDMOs and various challenges facing the industry.

Did you know Catalent has newly expanded in-house capabilities spanning clinical and commercial scale manufacturing for DPIs, unit-dose, bi-dose and preserved multi-dose nasal sprays?